This is the authors' abstract. We don't add key points for this paper.
Purpose of review: Desmoid tumors are rare benign fibroblastic tumors. Although benign, a small proportion is locally quite aggressive and may be fatal. There are only limited data upon which strategies for management may be based. Available studies are largely single institutional retrospective experiences, but new treatment outcome data have become available in recent years that will facilitate our management in treating these tumors. Herein, we review recent studies of biology, natural history, treatment, and outcomes of patients with desmoid tumors. Recent findings: Surgery has been and is the first-line therapy for patients with desmoid tumors. Radiation has been employed as adjuvant therapy or the definitive treatment for unresectable disease. Recent studies have demonstrated that radiation alone or combined modality therapy for margin positive or gross residual disease may provide improved disease control relative to that by surgery alone. However, importance of margin status and disease status (primary vs recurrent) continues to be controversial. Additionally, quite good results are being obtained by several low toxicity hormonal or chemotherapy protocols in an important proportion of patients, and such therapy may be especially important for intraabdominal desmoids. Summary: Optimal therapy for desmoid tumors has not been defined. Radiation, surgery, and combined modality therapy each provide high rates of disease control. With rapidly expanding techniques to study genetics and molecular pathways, a new era of understanding this clinically heterogeneous population of tumors is opening. The expectations are that effective targeted therapy will be developed in the not too distant future.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Shih et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: